Liver Cirrhosis Market

Liver Cirrhosis Insights and Trends

• The liver cirrhosis market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2026–2036). This growth in market revenue is primarily propelled by the rising prevalence of chronic liver diseases, increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), alcohol-related liver disease, viral hepatitis, improved diagnostic capabilities, and growing awareness leading to earlier disease identification across the 7MM.
• DelveInsight suggests that within the 7MM, there are more than 3 million diagnosed prevalent cases of liver cirrhosis in 2025. Notably, the US contributes approximately majority of these cases, indicating a significant burden within the country compared to other nations in the 7MM.
• The market size of liver cirrhosis influenced by various factors such as the pharmaceuticals and treatment options available for managing the condition, prevalence of liver cirrhosis, advancements in treatment options, healthcare infrastructure, and reimbursement policies.
• The increasing burden of liver cirrhosis may be attributed to a combination of factors, including the growing prevalence of obesity, diabetes, metabolic syndrome, excessive alcohol consumption, chronic hepatitis B and C infections, aging populations, and improved survival of patients with chronic liver disease.
• Although no approved therapy currently reverses liver cirrhosis, advances in disease management have significantly improved patient outcomes. Current treatment strategies focus on addressing the underlying cause, slowing disease progression, preventing complications such as portal hypertension, ascites, and hepatic encephalopathy, and optimizing supportive care. Combined with ongoing innovation in antifibrotic and regenerative therapies, these approaches offer promising opportunities to improve long-term outcomes and reduce the need for liver transplantation.
• Investigational drugs, including antifibrotic agents, anti-inflammatory therapies, and regenerative therapies, such as belapectin and efruxifermin are being evaluated to improve the management of liver cirrhosis. Several additional candidates are in various stages of clinical development, indicating a promising pipeline that is expected to expand future treatment options
• The future liver cirrhosis market is expected to become increasingly competitive as multiple novel therapies targeting fibrosis, inflammation, metabolic dysfunction, and liver regeneration advance through clinical development. The potential introduction of effective disease-modifying treatments could significantly transform the treatment landscape, improve patient outcomes, and accelerate overall market growth at a notable CAGR during the forecast period.

DelveInsight’s “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of liver cirrhosis, historical and forecasted epidemiology, as well as the liver cirrhosis market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The liver cirrhosis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, liver cirrhosis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022–2036) across the 7MM regions. The report highlights key unmet medical needs in liver cirrhosis and maps the competitive and clinical landscape to uncover high‑value opportunities, providing a clear outlook on future market growth potential.

Geography Covered

North America: The United States 

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Liver Cirrhosis Understanding and Treatment Algorithm

Liver Cirrhosis Overview and Diagnosis

Cirrhosis is the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, leading to portal hypertension and end-stage liver disease. In this late-stage liver disease, the healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged, and scar tissue keeps the liver from working properly. Cirrhosis has many signs and symptoms, such as fatigue and severe itchy skin, and they may not appear until the liver is badly damaged. Causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.

Most patients with early-stage cirrhosis are asymptomatic, and the disease is often detected incidentally through routine blood tests or imaging. Although liver biopsy remains the gold standard for confirming cirrhosis, it is an invasive procedure that many patients find uncomfortable. As symptoms such as jaundice appear only in advanced, irreversible stages, opportunities for early intervention are often missed. Current diagnostic approaches, including imaging and liver function tests, have limited sensitivity for detecting early disease and predicting progression, highlighting the need for more accurate, reliable, and non-invasive biomarkers for early diagnosis and disease monitoring.

Further details related to country-based variations are provided in the report…

Current Liver Cirrhosis Treatment Landscape

Treatment for cirrhosis depends on the underlying cause and the stage of disease. Although cirrhosis is generally irreversible, early management of the underlying condition, such as viral hepatitis or hemochromatosis, can slow disease progression, prevent liver failure, and may partially improve liver scarring. Supportive measures, including a balanced high-protein, low-fat diet, regular exercise, and management of nutritional deficiencies, also play an important role in improving patient outcomes and quality of life.

Patients with decompensated cirrhosis often develop serious complications, including ascites, hepatic encephalopathy, and variceal bleeding, which require intensive medical care and significantly impair daily functioning. Current treatments, such as medications, IV antibiotics, endoscopic procedures, and hemodialysis, are often expensive, associated with adverse effects, and may provide limited long-term benefit. Liver transplantation remains the only definitive treatment for end-stage cirrhosis; however, its high cost and the shortage of donor organs leave many patients without timely access. These challenges highlight the need for more effective, accessible, and affordable therapies to reduce complications and improve long-term outcomes.

Further details related to country-based variations are provided in the report…

Liver Cirrhosis Epidemiology

The epidemiology section of the liver cirrhosis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of liver cirrhosis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings from Liver Cirrhosis Epidemiological Analysis and Forecast

• The US showed the highest diagnosed prevalent population of liver cirrhosis compared to the other 7MM countries, with more than 2 million cases in 2025. As per DelveInsight’s estimates, the country alone accounts for nearly 61% of total diagnosed prevalent cases, for liver cirrhosis in the 7MM, followed by Japan, contributing 15% of all the liver cirrhosis cases.
• The etiology-specific distribution of diagnosed prevalent cases of liver cirrhosis showed NASH, HCV, HVB, ALD, and PBC comprised 28%, 27%, 11%, 33%, and 2% cases, respectively in the 7MM in 2025.
• EU4 and the UK accounted for approximately 1 million diagnosed prevalent cases of liver cirrhosis in 2025. Of these cases, Germany accounted for the highest number of diagnosed prevalent cases of liver cirrhosis between EU4 and the UK.
• Japan accounted for more than 500,000 cases of the total diagnosed prevalent cases of liver cirrhosis in the 7MM in 2025.

Liver Cirrhosis Market Outlook

The liver cirrhosis therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2026–2036).

With ongoing research and continued dedication, the future holds hope for effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the liver cirrhosis market in the 7MM is expected to change significantly during the forecast period 2026-2036.

Liver Cirrhosis Drug Analysis & Competitive Landscape

The liver cirrhosis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the liver cirrhosis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the liver cirrhosis therapeutics market.

Liver Cirrhosis Pipeline Analysis

Efruxifermin: Akero Therapeutics

Efruxifermin (EFX), formerly AKR-001, is Akero’s lead product candidate for MASH cirrhosis. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine if approved. EFX is currently being evaluated in Phase IIb clinical trials in patients with biopsy-confirmed NASH: the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. EFX shows the potential to be an effective treatment for patients with cirrhosis due to MASH. Currently the drug is in Phase II of clinical development for the treatment of MASH cirrhosis.

Note: Detailed emerging therapies assessment will be provided in the final report…

Liver Cirrhosis Market Outlook

DelveInsight’s ‘Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a detailed outlook of the current and future liver cirrhosis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Liver Cirrhosis Market Size by Countries

The liver cirrhosis market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2025, the US held a significant share of the overall 7MM (Seven Major Markets) liver cirrhosis market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products. 

Country-wise Market Size Distribution of Liver Cirrhosis

Liver Cirrhosis Market Size by Therapies

Liver Cirrhosis market size by therapies is categorized into current and emerging markets for the study period 2022–2036. 

Note: Detailed market segment assessment will be provided in the final report.

Liver Cirrhosis Drug Uptake

This section focuses on the sales uptake of potential of liver cirrhosis drugs that have recently been launched or are anticipated to be launched in the liver cirrhosis market between 2022 and 2036. It estimates the market penetration of liver cirrhosis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the liver cirrhosis market.

The emerging liver cirrhosis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfil in the liver cirrhosis market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on liver cirrhosis

Liver Cirrhosis Market Access and Reimbursement

DelveInsight’s ‘Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast – 2036’ report provides a descriptive overview of the market access and reimbursement scenario of liver cirrhosis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

Key Opinion Leaders (KOLs) Views

To keep up with current liver cirrhosis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the liver cirrhosis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or liver cirrhosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the liver cirrhosis unmet needs.

Liver Cirrhosis: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Duke University School of Medicine, University of Florida Gainesville, Stanford University, Liver Unit, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, University of Florida Gainesville, Florida, Service des Maladies de l'Appareil digestif, Hôpital Huriez, CHU, Lille, France, Liver Unit, Hospital Clinic of Barcelona, Barcelona, Spain, Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, among others.

Note: Detailed assessment of KOL Views will be provided in the full report on liver cirrhosis

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the liver cirrhosis Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Liver Cirrhosis Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for liver cirrhosis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging liver cirrhosis therapies.

Liver Cirrhosis Report Insights

• Liver Cirrhosis Patient Population
• Therapeutic Approaches
• Liver Cirrhosis Pipeline Analysis
• Liver Cirrhosis Market Size and Trends
• Liver Cirrhosis Market Opportunities
• Impact of Upcoming Therapies

Liver Cirrhosis Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Liver Cirrhosis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Liver Cirrhosis Market
• Liver Cirrhosis Drugs Uptake

Liver Cirrhosis Report Assessment

• Liver Cirrhosis Current Treatment Practices
• Unmet Needs
• Liver Cirrhosis Pipeline Product Profiles
• Liver Cirrhosis Market Attractiveness

Key Questions

• How common is liver cirrhosis?
• What are the key findings of liver cirrhosis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022–2036)?
• What are the currently available treatments for liver cirrhosis?
• What are the disease risk, burden, and unmet needs of liver cirrhosis?
• At what CAGR is the liver cirrhosis market and its epidemiology is expected to grow in the 7MM during the forecast period (2026–2036)?
• How would the unmet needs impact the liver cirrhosis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of liver cirrhosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026–2036)?
• How many companies are currently developing therapies for the treatment of liver cirrhosis?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the liver cirrhosis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of key opinion leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future. 
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What are the treatment goals for liver cirrhosis?

The primary goals in the treatment of liver cirrhosis are to halt or slow disease progression by addressing the underlying cause, prevent further liver injury and fibrosis, manage complications such as portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and hepatocellular carcinoma, preserve liver function, reduce morbidity and mortality, improve quality of life, and ultimately delay or avoid the need for liver transplantation. Comprehensive multidisciplinary care is essential to optimize outcomes in both compensated and decompensated cirrhosis.

2. What are the challenges in managing liver cirrhosis?

Managing liver cirrhosis presents several challenges, including delayed diagnosis due to the often asymptomatic nature of early-stage disease, the irreversible nature of advanced hepatic fibrosis, and the complex management of multiple complications that arise as liver function deteriorates. Additional challenges include limited availability of therapies capable of reversing established fibrosis, high rates of hospitalization and healthcare utilization, poor prognosis in decompensated disease, variability in disease progression among patients, and the growing burden of cirrhosis driven by metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), alcohol-related liver disease, and chronic viral hepatitis.

3. What are the key factors driving the growth of the liver cirrhosis market?

The liver cirrhosis market is driven by the increasing global prevalence of chronic liver diseases, particularly MASLD/MASH and alcohol-related liver disease, rising rates of obesity, diabetes, and metabolic syndrome, growing awareness and improved diagnostic capabilities enabling earlier detection, increasing healthcare expenditure, and ongoing research into novel anti-fibrotic and regenerative therapies. Additionally, the expanding pipeline of disease-modifying treatments, advances in biomarker development, and the substantial unmet need for effective therapies capable of reversing fibrosis are expected to support market growth throughout the forecast period.

4. How will the Liver Cirrhosis Market and Epidemiology Forecast Report benefit clients?

The report provides comprehensive insights into the current liver cirrhosis market landscape, epidemiological trends across the 7MM, disease burden, patient segmentation, and evolving treatment paradigms. It offers detailed analyses of emerging therapies, clinical development activities, competitive intelligence, regulatory developments, market drivers and barriers, and key unmet medical needs. These insights support informed business decisions, strategic planning, opportunity assessment, partnership evaluation, and market-entry strategies for stakeholders operating within the hepatology and chronic liver disease sectors.